Current developments in extracellular-regulated protein kinase (ERK1/2) inhibitors

Drug Discov Today. 2022 May;27(5):1464-1473. doi: 10.1016/j.drudis.2022.01.012.

Yuzhen Niu ¹, Hongfang Ji ²

Affiliations

1 Shandong Provincial Research Center for Bioinformatic Engineering and Technique, School of Life Sciences and Medicine, Shandong University of Technology, Zibo 255000, Shandong, PR China. Electronic address: niuyzh329@sdut.edu.cn.
2 Shandong Provincial Research Center for Bioinformatic Engineering and Technique, School of Life Sciences and Medicine, Shandong University of Technology, Zibo 255000, Shandong, PR China. Electronic address: jhf@sdut.edu.cn.

PMID: 35104620 DOI: 10.1016/j.drudis.2022.01.012

Abstract

Extracellular signal-regulated kinases 1 and 2 (ERK1/2) are important members of the Ras signaling pathway. They are abnormally expressed in many diseases and, thus, are considered key therapeutic targets of human diseases. In this review, we summarize the importance of the ERK1/2 signaling pathway in the treatment of different diseases and inhibitors of ERK1/2 in clinical or preclinical research. We also discuss the main approaches used to discover ERK inhibitors, including the application and advantages of computer-aided drug design (CADD) approaches.

Keywords

CADD; Computer-aided drug design; ERK1/2; ERK1/2 inhibitors; Extracellular regulated protein kinase 1/2.

Name
Email *

	Sorry, but the email address you supplied was invalid.